Drug Trial Radar · NCT07054606
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
Last checked: Nov 20, 2026Latest source record: Dec 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
104
Actual
Start
Jul 2, 2025
Primary completion
Nov 3, 2025
Study completion Nov 3, 2025
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jul 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assess the impact of concomitant Miebo use while wearing contact lenses
Conditions
- Dry Eye
Interventions
Perfluorohexyloctane ophthalmic solutionDrug
Eligible subjects will receive Miebo up to 4 times bilaterally on Day 1/Visit 1 (1 drop instilled bilaterally by site staff in-clinic while wearing contact lenses and the rest self-administered throughout the remainder of the day while wearing contact lenses). Starting on Day 2, subjects will self-administer the first drop of Miebo bilaterally before inserting contact lenses for the day. Subjects will wait 30 minutes after the first dose of Miebo to insert their contact lenses and will then instill 3 additional drops of Miebo while wearing contact lenses approximately evenly spaced throughout the rest of the day. Subjects will continue to self-administer Miebo QID bilaterally following the dosing schedule from Day 2 for approximately 30 days. Subjects are expected to record daily VAS assessments throughout the study. The VAS assessments will be collected by the sites at Visits 2, 3, and 4.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline (CFB) in CLDEQ-8 score at Visit 4Time frame: Assessed for approximately 30 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Site 101
San Diego, California
Site 107
Longwood, Florida
Site 104
Pittsburg, Kansas
Site 102
Medina, Minnesota
Site 108
Vestal, New York
Site 103
Athens, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.